CASI Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $81.5M | — |
| FY2021 | — | $84.5M | $38.7M |
| FY2022 | — | $44.6M | $47.1M |
| FY2023 | $18.9M | $24.2M | $17.1M |
| FY2024 | — | $1.9M | $13.5M |
| FY2025 | — | $-37.3M | $5.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $81.5M | — |
| FY2021 | — | $84.5M | $38.7M |
| FY2022 | — | $44.6M | $47.1M |
| FY2023 | $18.9M | $24.2M | $17.1M |
| FY2024 | — | $1.9M | $13.5M |
| FY2025 | — | $-37.3M | $5.6M |